Nearly every figure quoted in favor of moving from semaglutide to tirzepatide was generated by giving tirzepatide to someone who had never taken an incretin drug. That is a different event from the one a person on 2.4 mg is contemplating, and the gap between the two is where this decision actually lives. Which molecule performs better from a standing start is settled well enough, and set out in the head-to-head article. What follows is the narrower question: what is known about the crossing itself.
The comparison trial randomized initiations, not transitions
SURMOUNT-5 assigned 751 adults with obesity and no diabetes to the maximum tolerated dose of one drug or the other for 72 weeks, and tirzepatide won on weight and on waist circumference.[1] The design detail that matters here is buried in the dosing arms. Tirzepatide participants began at 2.5 mg and rose in 2.5 mg steps every four weeks; semaglutide participants began at 0.25 mg and rose every four weeks to 1.7 or 2.4 mg.[1] Randomization happened at week zero. Nobody in that trial was carrying a year of exposure to the other molecule when their first injection was given.
So the result describes two ways of beginning treatment. It cannot describe what a body already adapted to a GLP-1 receptor agonist does when a second incretin receptor is added to the picture, and it says nothing about the arithmetic on the tirzepatide board for someone who is already paying for semaglutide.
The switch trials that do exist start from a weaker drug
SURPASS-SWITCH is the only randomized trial built around this shape. It enrolled 282 adults with type 2 diabetes who had been on a stable dose of dulaglutide — 0.75 or 1.5 mg — for at least six months, and randomized them either to escalate dulaglutide to 4.5 mg or maximum tolerated dose, or to switch to tirzepatide at 15 mg or maximum tolerated dose. At week 40, HbA1c fell 1.44% on tirzepatide against 0.67% on dulaglutide, an estimated treatment difference of −0.77% (95% CI, −0.98% to −0.56%; P < 0.001), and weight fell 10.5 kg against 3.6 kg, a difference of −6.9 kg (95% CI, −8.3 to −5.5 kg). Serious adverse events were reported by 7.2% of the tirzepatide group and 7.0% of the dulaglutide group.[2]
A prespecified subgroup analysis split that cohort by age, baseline HbA1c, diabetes duration, body-mass index, sex, ethnicity and — the relevant one — baseline dulaglutide dose. Reductions favored tirzepatide consistently across all of them, with a similar safety profile and nausea and diarrhea as the usual leading adverse events.[3] The ceiling on that reassurance is the exposure being left behind: the highest prior dose studied is dulaglutide 1.5 mg, a third of dulaglutide’s own maximum and a different molecule from the one this page is about.
One further trial went straight at the starting-rung question. SURPASS-SWITCH-2 was a single-arm phase 4 study in which 152 adults with type 2 diabetes, each on a stable GLP-1 receptor agonist for at least three months, moved directly onto tirzepatide 5 mg for 12 weeks — skipping the 2.5 mg initiation dose entirely. HbA1c fell 0.43% (SE 0.05). Of the 152, 131 completed, one discontinued for an adverse event, and no non-serious adverse event reached the 5% reporting threshold.[4] That trial has posted results and no journal publication, it ran in diabetes rather than obesity, and 12 weeks is too short to say anything about weight.
The number reverses when the switchers are split by reason
A 2026 retrospective cohort screened 941 charts and analyzed 293 adults prescribed tirzepatide, classifying anyone who had lost 10% or more of total body weight beforehand as weight-reduced. At six months the weight-reduced group (n = 133) lost 7.2% of total body weight against 10.3% in the group that was not (n = 160), P < 0.001 — a difference that persisted among patients without type 2 diabetes.[5]
Inside that cohort sat 61 people who had switched from therapeutic semaglutide, defined as 1.7 mg weekly or more for at least a month, because of non-response or plateau. Pooled, they lost 5.3% of total body weight. Split by reason, the pooled figure falls apart: those switching at a plateau (n = 28) lost 8.1%, while those switching as non-responders (n = 33) lost 2.9%, P < 0.001.[5]
Read the direction carefully, because marketing runs it backwards. The patient with the strongest intuitive case for changing drug — semaglutide did almost nothing — is the patient the data gives the smallest expected return. The patient who did respond and then stalled kept roughly the result an average new starter gets. What a stall is and is not has its own page in the plateau article. This is one retrospective cohort at a single practice, with 28 and 33 people in the cells that carry the finding, so it is a signal about direction rather than a number to plan around.
What the labels say about initiating, and what they omit
The tirzepatide label is unambiguous about where treatment begins. Section 2.1 of the Zepbound prescribing information states that “the recommended starting dosage of ZEPBOUND for all indications is 2.5 mg injected subcutaneously once weekly for 4 weeks,” that “the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage,” and that the dose may then be increased in 2.5 mg increments after at least four weeks on the current dose.[6] Mounjaro carries the same 2.5 mg start and the same four-week increment.[10] The full climb is mapped in the tirzepatide dosing article and the titration schedule.
Now the omission. No dosing section in that label conditions the starting rung on anything a patient took before. There is no prior-exposure clause, no credit for a tolerated semaglutide dose, and no alternative schedule for a patient transferring in. The one sentence in the label that mentions the other class runs the opposite way: the Limitations of Use state that “coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”[6]
That silence is not a drafting oversight, and the Wegovy label proves it. Its section 2.5 is titled “Switching Between WEGOVY Injection and WEGOVY Tablets,” and it gives the interval and the destination dose: “one week after discontinuing WEGOVY 2.4 mg injection, initiate 25 mg of WEGOVY tablets orally once daily.”[7]When a switch has been studied, the label carries instructions for it. Between molecules, no label carries any.
Whether tolerance carries over
The practical version of the question is whether a year without nausea on semaglutide buys a higher starting rung on tirzepatide. What has been measured is the adverse-event profile of two initiations. In SURMOUNT-5, nausea was reported by 163 of 374 tirzepatide participants (43.6%) and 167 of 376 on semaglutide (44.4%), vomiting by 56 against 80, and gastroesophageal reflux by 23 against 40 — with gastrointestinal events mostly mild to moderate and occurring primarily during dose escalation.[1] Those are the numbers for climbing a ladder from the bottom, which is what both arms did.
The nearest thing to a re-escalation measurement is SURPASS-SWITCH-2: 152 people moved onto 5 mg without the 2.5 mg rung, and over 12 weeks a single participant stopped for an adverse event.[4] A smaller retrospective series took the opposite approach — 15 patients with type 2 diabetes switching off semaglutide 1.0 mg all restarted at 2.5 mg, and those escalated to 10 mg showed an HbA1c reduction of 0.7% ± 0.3% (P < 0.01) against no significant change in the group held at 7.5 mg.[8] Neither study stratified gastrointestinal events by the dose the patient came off, which is the comparison the question actually needs. Symptom timing on a fresh escalation is covered in the nausea article.
The only labeled rule touching prior exposure points downward, not upward. The Wegovy label instructs that if two or more consecutive injections are missed, prescribers should “reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions.”[7] Within a single molecule, a gap in exposure means going back down.
The absence, with its census
No randomized trial has assigned patients established on semaglutide to either continue it or cross to tirzepatide. A PubMed search on September 14, 2026 for records carrying both molecules in the title or abstract alongside a switch or transition term and a randomized descriptor returns five records: four are narrative reviews, systematic reviews or network meta-analyses, and the fifth is a model-based dose-response analysis. None reports such a trial. ClinicalTrials.gov lists exactly two interventional studies with “switch” in the title and tirzepatide as the intervention — SURPASS-SWITCH and SURPASS-SWITCH-2 — both in type 2 diabetes, one starting from dulaglutide and the other single-arm.[2][4]
Everything a seller or a forum says about the crossover therefore rests on a diabetes trial that began from a different drug, a 12-week single-arm registry record, and one retrospective chart review. That is a thin base for a change that can add hundreds of dollars a year, which the cost calculator will put a figure on.
What the compounded market does with the gap
Most sellers listed here dispense both molecules, which makes a switch a plan change rather than a clinical event. Compounded semaglutide and compounded tirzepatide are prepared by a pharmacy against a prescription and are not FDA-approved; they are not reviewed by the FDA for safety, efficacy or quality before dispensing, and the differences from branded product are set out in the compounded article. Because there is no label, there is also no labeled starting dose, no labeled escalation interval, and nothing external fixing where a transferring patient begins.
The commercial gradient runs one way. Tirzepatide generally costs more, so a conversation that ends in a switch ends in a larger subscription, and no evidence above obliges a prescriber to hold a switching patient at the bottom of the ladder or to move them up it. Both choices are defensible and neither is measured, which is precisely the condition in which a revenue incentive decides. Worth asking before agreeing: what dose the first vial contains, what the washout interval is, and whether the price changes with the dose.
Cost is also the most common reason these prescriptions end. Among 288 adults in an Ohio and Florida health system who discontinued semaglutide or tirzepatide within the first year, 137 (47.6%)stopped over cost or insurance, 42 (14.6%) could not tolerate side effects, 34 (11.8%) could not fill the prescription during shortages, and 7 (2.4%) moved to a compounded medication.[9] Unsatisfactory weight loss accounted for 5 patients, or 1.7%.[9] The reason people leave these drugs is mostly the bill, not the molecule.
What a person on 2.4 mg can take from this
Three things hold. The large superiority figures for tirzepatide were measured in people starting treatment, and no randomized result extends them to someone crossing over. The label sets one starting dose and one escalation interval and does not vary either for prior exposure. And in the one cohort that split switchers by reason, the expected gain depended on why the switch was happening — a plateau and a non-response produced results nearly three-fold apart.
None of that decides an individual case, which belongs to a prescriber holding a chart rather than to a checkout page. What this site publishes is what the sellers state and what the trials measured, recorded in the seller write-ups and established the way the methodology describes.